AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, today announced its entry into a binding letter of intent (“LOI”) with Asymchem, a leading global contract development and manufacturing service (“CDMO”) provider, for the development and production of MS1819 for the treatment of exocrine pancreatic insufficiency. Under the … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Enters LOI with Asymchem for MS1819 Development, Production”
AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, earlier this year announced the closing of a private placement financing (the “offering”). According to the update, AzurRx secured approximately $6.9 million in gross proceeds from certain accredited investors, with Alexander Capital LP acting as sole placement agent in … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures $6.9M in Private Placement”
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, in July entered into a convertible preferred stock and warrant securities purchase agreement with certain accredited and institutional investors relating to the private placement of certain shares of convertible preferred stock and warrants for cash and in exchange for certain outstanding promissory notes as described in a recent … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures Financing to Fund Phase 2 Clinical Trials and Phase 3 Preparations”
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, recently announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Positive Results in Ongoing Phase 2 Combination Therapy Trial with MS1819”
AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company focused on developing treatments for gastrointestinal diseases using recombinant proteins, has announced the formation of a Scientific Advisory Board (“SAB”) designed to provide the company with invaluable expertise and insights. The company also announced that three leading global experts in exocrine pancreatic insufficiency (“EPI”) in patients with cystic … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Forms New Scientific Advisory Board”
AzurRx BioPharma’s lead therapeutic, MS1819, is a recombinant lipase treatment for exocrine pancreatic insufficiency and is currently targeting patients with cystic fibrosis and chronic pancreatitis – an established global market of more than $2 billion The company is currently pursuing parallel monotherapy and combination therapy trials, which are anticipated to produce topline data in Q1 … Continue reading “AzurRx BioPharma Inc. (NASDAQ: AZRX) is “One to Watch””
AzurRx BioPharma (NASDAQ: AZRX) has activated additional clinical trial sites for its trial of MS1819 in cystic fibrosis. The company specializes in the development of nonsystemic, recombinant therapies for gastrointestinal diseases. The company has activated two additional trial sites in Turkey for its Phase 2 combination therapy trial of its lead drug candidate, MS1819. MS1819 is a recombinant … Continue reading “NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Adds More Sites for Cystic Fibrosis Clinical Trials”
AzurRx BioPharma Inc. (NASDAQ: AZRX) is a biopharmaceutical company specializing in the research and development of non-systemic biologics for gastrointestinal disorders. The company is focused on the development of its lead drug candidate, MS1819. AzurRx is currently conducting two Phase 2 clinical trials of MS1819: the OPTION 2 monotherapy trial and the combination therapy trial, … Continue reading “AzurRx BioPharma Inc. (NASDAQ: AZRX) Starts Presentation at The LD 500”
AzurRx BioPharma (NASDAQ: AZRX) is a business-led, science-driven, and clinically advanced development-stage biopharmaceutical company. AzurRx BioPharma is focused on the development of recombinant proteins for the treatment of gastrointestinal diseases and microbiome related conditions. The company’s lead development program, MS1819, is a recombinant lipase for the treatment of exocrine pancreatic insufficiency indicated for cystic fibrosis … Continue reading “AzurRx BioPharma Inc. (NASDAQ: AZRX) Starts Presentation at Dawson James Small Cap Growth Conference”
AzurRx BioPharma (NASDAQ: AZRX) is engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. MS1819 recombinant lipase for exocrine pancreatic insufficiency is the company’s lead development program, and additional early stage research is being conducted for the prevention of hospital-acquired infections. The company is headquartered in Brooklyn, … Continue reading “AzurRx BioPharma Inc. (NASDAQ: AZRX) Attends 31st Annual ROTH Conference”
